16 research outputs found
Small bowel motility affects glucose absorption in a healthy man
WST臉P. Celem pracy by艂o wyja艣nienie zwi膮zku pomi臋dzy motoryk膮
dwunastnicy i jelita cienkiego a wch艂anianiem glukozy oraz ustalenie wp艂ywu zmiany
motoryki jelita cienkiego na wch艂anianie glukozy po zastosowaniu substancji prokinetycznej
- cizaprydu.
MATERIA艁 I METODY. W badaniu wzi臋艂o udzia艂 7 zdrowych m臋偶czyzn,
kt贸rych 艣rednia wieku wynosi艂a 22 lata. W spos贸b randomizowany badani otrzymywali
cizapryd 10 mg 3 razy dziennie lub placebo, przez 3 dni. Po 2 tygodniach powtarzano
pr贸b臋 z drugim preparatem. Rano 3 dnia badania wykonywano manometri臋 z u偶yciem
18-kana艂owego cewnika, wprowadzonego do dwunastnicy. Przez 30 minut badani otrzymywali
przez cewnik p艂ynn膮 od偶ywk臋 (3 kcal/min), a nast臋pnie bolus analogu glukozy
(3-OMG, 3-O-metyloglukoz臋). W celu oceny kinetyki wch艂aniania oznaczano w osoczu
st臋偶enia 3-OMG.
WYNIKI. Pole pod krzyw膮 st臋偶enia 3-OMG w pierwszych 30 minutach
po podaniu dojelitowym by艂o zale偶ne od liczby ruch贸w robaczkowych rozchodz膮cych
si臋 ortodromowo (r = 0,49, p < 0,05), ale nie wykazano zwi膮zku ze st臋偶eniem szczytowym,
czasem do osi膮gni臋cia st臋偶enia szczytowego ani frakcj膮 wch艂oni臋t膮. 艢rednia amplituda
ruch贸w robaczkowych by艂a wy偶sza przy podawaniu cizaprydu ni偶 placebo (p < 0,05),
ale powr贸t motoryki w okresie mi臋dzyposi艂kowym, liczba ruch贸w robaczkowych i ich
propagacja oraz charakterystyka wch艂aniania 3-OMG by艂y podobne przy stosowaniu
cizaprydu i placebo. W obu typach leczenia propagacja ruch贸w robaczkowych w ponad
60% wynosi艂a jedynie 1,5 cm.
WNIOSKI. Absorpcja glukozy w jelicie cienkim cz艂owieka wi膮偶e
si臋 z propagacj膮 aktywno艣ci skurczowej jelita w zakresie kr贸tkich odcink贸w. Cizapryd
zwi臋ksza amplitud臋 ruch贸w robaczkowych, ale nie wp艂ywa na ich organizacj臋 ani
na wch艂anianie 3-OMG.INTRODUCTION. To investigate the relationship between
duodenojejunal motor activity and glucose
absorption and to evaluate the effect of modification
of duodenojejunal motility on glucose absorption
by using the prokinetic drug cisapride.
MATERIAL AND METHODS. We examined seven healthy
males, mean age 22 years, who were treated
with cisapride 10 mg t.i.d. and placebo during 3 days
in a randomized order, with a 2-week time interval.
Duodenojejunal manometry was performed after
each treatment on the morning of day 3, using an
18-lumen catheter. A liquid nutrient (3 kcal/min) was
administered intraduodenally for 30 min, followed
by a bolus of the glucose analog 3-O-methylglucose
(3-OMG). Plasma 3-OMG concentrations were measured
to assess absorption kinetics. RESULTS. The area under the 3-OMG concentration
curve in the first 30 min after infusion was related
to the number of antegrade propagated pressure
waves (r = 0.49, P < 0.05), but not to the peak concentration,
time to peak, and absorption fraction.
The mean amplitude of pressure waves was higher
during cisapride than placebo (P < 0.05), but the
reoccurrence of interdigestive motility, numbers of
pressure waves, and propagated pressure waves, as
well as 3-OMG absorption characteristics, were not
significantly different between the two treatments.
During both treatments > 60% of antegrade propagated
pressure waves were propagated over a very
short distance (1.5 cm).
CONCLUSIONS. Glucose absorption in the human
small intestine is related to short-traveling propagated
intestinal contractile activity. Cisapride increases
the amplitude of pressure waves, but does not
affect the organization of pressure waves or the
absorption of 3-OMG
Clinical and basal aspects of anemia during antiviral therapy for hepatitis C
Background and Rationale. Anemia is a major side effect of combination therapy for chronic hepatitis C. In this study, severity, potential risk factors for and potential underlying mechanisms of anemia were evaluated.Patients and methods. 44 chronic hepatitis C patients on interferon-ribavirin treatment were included. Anemia-related parameters were measured before and during treatment. Potential changes in membrane phospholipids composition of erythrocytes of patients on anti-viral treatment and potentially increased erythrocyte susceptibility to osmotic or bile salt induced stress were explored.Results. Anemia was almost universal during treatment, with evidence of hemolysis. Decrease of Hb after six months of therapy was 2.1 卤 O.I mmol/L (range -0.6-4.1). Higher pre-treatment Hb, highest ribavirin dose (1S-17.S mg/kg) and lower pre-treatment platelet level were independent risk factors for decrease of Hb. Serum erythropoietin levels increased during treatment with negative correlation to Hb levels at week 12 (r = -0.70, p = 0.002) and 24 (r = -0.72, p = 0.002). Erythrocyte membrane phospholipid composition did not differ between anemic patients and healthy controls. Also, resistance to osmotic or bile salt induced stress was normal in anemic patients. Phosphatidylserine exposure at the outer membrane leaflet did not change upon 24 hrs ex vivo incubation with pharmacological ribavirin concentration.Conclusions. Anemia is almost universal during anti-HCV treatment. The extent of anemia correlates with pre-treatment levels of thrombocytes and Hb and with high ribavirin dosing. Although we found hemolysis as contributing factor, our data do not indicate that altered membrane phospholipids composition is an important factor in pathogenesis of anemia